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Broncho-alveolar lavage (BAL) is important to assess airway inflammation. There is debate
about the volume instilled, but the variation of BAL fluid recovery (BFR) has received little
attention. We investigated the association between BFR and rejection/infection status
after lung transplantation (LTx).
We combined clinical findings, FEV1, transbronchial biopsies and BAL analysis (BFR,
interleukin-8 (IL8), cell counts, microbiology) of 115 samples/LTx patients. The patients
were divided into 4 groups: stable (subdivided in colonized and non-colonized), acute
rejection (AR), Bronchiolitis Obliterans Syndrome (BOS) and infection.
BFR was significantly lower in AR, BOS and infection, and correlated with the severity of AR
and BOS. A 10ml decrease of BFR was associated with a FEV1 decrease of 4.4% and a
%neutrophils and IL8 increase of 9.6% and 9.7 pg/ml, respectively. Colonized stable
patients had no significant differences in airway inflammation, FEV1 and BFR compared to
the non-colonized stable patients.
We conclude that a low BFR is an indicator of lung rejection or infection. BFR variation is
related to airway obstruction and neutrophilic inflammation, which can cause an increased
compliance of the airway wall, making it more collapsible. Airway colonization in stable
patients had no effect on airway inflammatory parameters, BFR and FEV1.
& 2007 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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B.M. Vanaudenaerde et al.340Introduction findings combined with TBB, measurement of bloodThe mechanisms of airway obstruction in acute and chronic
rejection after lung transplantation (LTx) are poorly under-
stood. Broncho-alveolar lavage (BAL) is a useful and safe
research method for sampling cells and mediators from the
upper and lower respiratory tract, to better understand the
pathophysiological mechanisms of allograft rejection. Until
now, research on the method of lavage was mainly focussed
on the volume used for instillation, because of the
heterogeneous cell distribution over the different frac-
tions.1,2 The early fractions represent a bronchial washing
and the later fractions rather represent an alveolar
washing.2
BAL fluid recovery (BFR) variations are, however, only
seldom reported. In COPD, BFR is only 10–40% of the instilled
volume.3 No differences were found between BFR of allergic
and non-allergic asthmatic children and between infected
and non-infected asthmatic children.4 In LTx, there is scarce
data about BFR.5 It is only briefly mentioned that BFR can be
decreased in patients with Bronchiolitis Obliterans Syn-
drome (BOS).6,7 Changes in BFR can complicate the
interpretation, because a low BFR may predominantly
reflect the inflammation in the larger airways.2 Recently,
Lofdahl et al.8 investigated for the first time more
specifically the role of BFR and showed a correlation of
BFR with the degree of emphysema. They, however, failed to
demonstrate a correlation with FEV1.
Based on our clinical experience and the article of Lofdahl
et al.,8 the idea was raised to investigate changes in BFR in
LTx. LTx recipients who participated in a routine follow-up
were included in this retrospective study. BFR and its
relation with BAL absolute and differential cell counts,
Interleukin-8 (IL8), acute and chronic rejection grade,
airway infection and FEV1 were investigated.Patients and methods
A total of 152 LTx patients underwent bronchoscopy with
BAL in combination with clinical examination, chest X-ray
and functional evaluation, as part of a longitudinal follow-up
study between October 2001 and December 2004. Routine
follow-up bronchoscopies were performed at 28, 90, 180,
360, 540, 720, 900 and 1080 days after LTx, by the same
operators in an identical way (LJD and GMV). Transbronchial
biopsies (TBB) were taken at days 28 and 90 after LTx and
when suspicion of acute rejection (AR) or infection (based
on clinical, radiological and pulmonary function criteria).
Exclusion criteria were: no BFR recorded, suture problems,
post-transplant lymphoproliferative disorder, presence of
other malignancies, diffuse alveolar damage or the combi-
nation of AR or BOS with another complication at one time
point. To eliminate the possibility of multiple sampling, only
the last BAL samples of each patient with adequate biopsy
and lung function tests was retained. Finally, 4 groups were
analyzed: a stable group (no histological or clinical proven
AR—no infection on biopsy or clinically suspected—no
OB/BOS based on FEV1, clinical examination or TBB), an
AR group (TBB proven and exclusion of other cumulating
problems), a BOS group (based on the ISHLT working
formulation)9 and an infection group (based on clinicalC-reactive protein (CRP) and exclusion of other cumulating
problems). Airway colonization, defined as the presence of
positive bacterial/fungal cultures in BAL without evidence
of CRP, new radiological infiltrates, fever or need for
antibiotic or antifungal treatment, was no exclusion
criterion. However, the patients with airway colonization
were analyzed separately to identify its effect on the
investigated parameters. This study was approved by the
Ethics Committee of UZ Gasthuisberg.
FEV1 was measured with the Masterscreen according to ATS
criteria10 as described before.11 Bronchoscopy was performed
with a bronchoscope (Olympus BF1T30, outer diame-
ter ¼ 5.9mm and channel diameter ¼ 2.8mm) under intra-
venous sedation with 5mg diazepam. TBB specimens were
examined for infection and AR (according to ISHLT guide-
lines).12 BAL was performed with two 50ml aliquots of sterile
saline, at room temperature, into the transplanted lung,
either in a subsegmental bronchus of the lingula or the right
middle lobe. After each 50ml instilled, the fluid was
recovered by gentle manual suction. The reason to use two
50ml fractions is documented in the discussion. The recov-
ered fractions were pooled and the volume noted. The BAL
was analyzed for microbiological, virological, cell counting
and IL8 protein. A cytospin (105 cells/ml) was stained with May
Gru¨nwald Giemsa, and at least 300 cells were counted. IL8
protein was analyzed in BAL supernatant by means of an ELISA
(Biosource SA, Nivelle, Belgium; sensitivity ¼ 2pg/ml). Cell
viability is not counted/recorded in our center, as Elssner et
al.13 and Riise et al.14 demonstrated cell viability not to be
associated with the development of BOS in lung transplant
patient. Moreover, BAL fluid is kept on ice and immediately
processed in the lab.
Statistical analyses were performed with SAS software
(version 8.1). All results were presented as median (IQR). In
the first part, one-way analysis of variance was used to
investigate the variation between the different groups and
Bonferroni multiple comparison test was used as post hoc
test. Dose–effect relationship was calculated by mean of
Spearman rank test. In the final part of our analysis, we
calculated the odds of having AR, BOS and/or infection
associated with a 1ml decrease of BFR. For regression
analysis non-normally distributed data were log trans-
formed. The first part showed no important variations with
log transformation of non-normally distributed data (and
accompanying normal statistical tests) and was therefore
not shown.Results
Study protocol
The current study included 152 LTx patients, who underwent
a total of 600 bronchoscopic procedures with BAL, together
with clinical, biochemical, radiological and pulmonary
function evaluation at the moment of bronchoscopy,
between October 2001 and December 2004. We excluded
37 patients based on the aforementioned exclusion criteria.
One hundred and fifteen patients with 115 BAL samples were
divided in a stable, AR, BOS and infection group. Patient’s
characteristics are given in Table 1.
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BAL and airway neutrophilia 341TBB was available in all 23 patients of the AR group,
demonstrating 12 A1, 8 A2 and 3 A3 grade AR. In the other
groups, biopsies were not always performed; however, in the
stable group 32/52 had a biopsy to exclude AR/infection.
The BOS group consisted of: 17 BOS1, 13 BOS2 and 1 BOS3.
20/31 patients with established BOS had a biopsy to confirm
the absence of AR/infection. The infection group consisted
of 5 patients with CMV pneumonia, 2 with a Pseudomonas
and 1 with Escherichia coli pneumonia and 1 with an acute
neutrophilic bronchiolitis. Total and/or differential cell
count could not be obtained in 4 samples (1 of the stable
group, 1 of the AR group and 2 of the BOS group), due to lysis
of the cells and impossibility for interpretation. These
patients were retained for analysis as most of the other
investigated parameters were available. Smoking cannot be
considered as a possible confounding factor as there were
within the total study group (n ¼ 115) only 4 patients who
restarted smoking as demonstrated by positive urine cotinin
test; 2 in the stable group; 1 in the AR group and 1 in the
infection group.BAL fluid recovery (BFR)
BFR, expressed as volume of the 100ml instilled (ml/100ml),
demonstrated significant changes between the 4 groups. BFR
of the AR, BOS and infection group were lower compared toTable 1 Group characteristics of patients.
Group Total Stable
n-Value 115 52
POD 245 (60–680) 183 (45–375)
Age 52(40–57) 50 (39–55)
Gender 49F/66M 22F/30M
LTx type
Bilateral 66 34
Unilateral 38 15
Heart–lung 11 3
Pre-LTx diagnosis
Emphysma 46 21
PF 24 13
CF 14 8
a1-ATD 7 1
Eisenmenger 6 2
PPH 5 1
Miscellaneous 13 6
Medication
FK506 89 37
CsA 26 15
MMF 35 13
AZA 68 32
Methylprednisolone 84 52
Rapamycin 5 0
POD ¼ post-operative day, LTx ¼ lung transplantation, PF ¼ pulm
deficiency, PPH ¼ primary pulmonary hypertension, miscellaneous ¼
myomatosis (1), obliterative bronchiolitis (1), asbestosis (1), sarcoido
MMF ¼ mycofenolate mofetil, AZA ¼ azathioprine.the control group (Table 2 and Figure 1A). No differences
were found between the AR, BOS and infection group. BFR
positively correlated with the degree of airway obstruction
measured as FEV1(%pred.) (r ¼ 0.24, p ¼ 0.0088, n ¼ 115,
Figure 1B) and negatively with the BOS grade (r ¼ 0.54,
po0.0001, n ¼ 83 (BOS group+stable group)) and the AR
grade (r ¼ 0.39, p ¼ 0.0005 and n ¼ 75 (AR group+stable
group)).
This variation in BFR was not influenced by the different
pre-transplant diagnosis as the proportions of the preLTx
diagnosis were not different between the study groups. Even
more, within the stable group BFR was not different for the
different pre-transplant diagnosis (unpublished data).BAL cellular profile
Total cells were not different between the 3 groups, while
absolute (p ¼ 0.025) and percentage (po0.0001) of neu-
trophils were significantly different between the groups.
Both absolute and percentages of neutrophils were higher in
BOS patients (po0.05 and o0.001, respectively) compared
with stable patients (Table 2). The percentages of macro-
phage demonstrated a significant difference (po0.0001) by
reason of compensating for the variations in neutrophils
(Table 2). Absolute lymphocyte counts showed a significant
variation (p ¼ 0.0033) with an increase in the infectionAR BOS Infection
23 31 9
41 (26–208) 1043(639–2151) 176 (90–467)
54 (46–59) 53(33–59) 54 (49–57)
10F/13M 13F/18M 4F/5M
14 12 6
8 13 2
1 6 1
9 13 3
6 3 2
2 4 0
2 2 2
1 3 0
1 3 0
2 3 2
14 29 9
9 2 0
5 15 2
17 12 7
23 31 9
0 5 0
onary fibrosis, CF ¼ cystic fibrosis, a1-ATD ¼ a1-anti-trypsin
bronchiectasis (5), retransplantation for BOS (3), Lymfangioleio-
sis (1), kartagener (1). FK506 ¼ tacrolimus, CsA ¼ cyclosporin A,
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Table 2 BFR, FEV1, cell differentials and IL8 levels.
Group Stable AR BOS Infection One-way analysis
of variance
FEV1 (% predicted) 79(53–98) 46(38–65)*** 56(40–62) 72(38–94) ND
BFR (ml/100ml) 46(40–55) 38(24–47)** 35(26–40)*** 30(23–45)** o0.0001
Total cells ( 103/ml) 140(98–274) 236(124–403) 179(60–369) 367(241–509) 0.16
Macrophages (%) 88(83–94) 84(47–93) 66(30–90)*** 45(34–53)*** o0.001
Macrophages ( 103/ml) 124(68–217) 169(66–230) 78(48–207) 142(73–299) 0.29
Neutrophils (%) 2.5(1.5–5.8) 8.0(1.8–49.5) 15.0(2.8–64.3)*** 46.5(20.7–55.0)** o0.0001
Neutrophils ( 103/ml) 2.7(1.1–11.5) 12.1(4.0–136.9) 12.2(3.6–231.5)* 134.1(53.4–315.9) 0.025
Lymphocytes (%) 6.5(2.8–11.0) 5.0(2.5–11.0) 5.3(2.0–9.3) 8.8(3.5–17.4) 0.73
Lymphocytes ( 103/ml) 9.4(3.1–24.0) 15.2(5.2–26.1) 7.1(2.6–23.0) 23.8(13.7–87.2)** 0.0033
Eosinophils (%) 0.0(0.0–0.0) 0.0(0.0–0.0) 0.0(0.0–0.5) 0.2(0.0–2.6) ND
Eosinophils ( 103/ml) 0.0(0.0–0.0) 0.0(0.0–0.0) 0.0(0.0–0.7) 0.6(0.0–5.6) ND
IL8 protein (pg/ml) 23(11–84) 50(16–181) 70(23–247)* 141(54–397)* 0.0097
Results are expressed as median (IQR) and statistically significant variation is calculated with one-way analysis of variance. ND ¼ not
determined. Bonferroni’s multiple comparison test is used as post hoc test for significances of the AR, BOS and infection group versus
the stable group. *po0.05, **po0.01, and ***po0.001.
B.M. Vanaudenaerde et al.342group compared to the stable group (po0.01, Table 2).
Eosinophils were neglectable (a median value under 1%).
BFR was negatively correlated with the numbers of
neutrophils, both expressed as a percentage (r ¼ 0.42,
po0.0001, n ¼ 113, Figure 1C) and as absolute number
(r ¼ 0.40, po0.0001, n ¼ 111). Neutrophil percentages
showed a significant negative correlation with FEV1
(r ¼ 0.31, p ¼ 0.0009, n ¼ 113, Figure 1E).
Analysis of IL8 protein in BAL
IL8 demonstrated significant variations between the 4
groups (p ¼ 0.0097). IL8 was increased in patients with
BOS (po0.05) or with infection (po0.05) compared with the
stable group. BFR correlated negatively with IL8 (p ¼ 0.37,
po0.0001, n ¼ 115, Figure 1D) and with the number of BAL
neutrophils (p ¼ 0.45, po0.0001, n ¼ 113).
Prognostic power of BFR
Logistic regression performed on all samples demonstrated
that, in comparison with the stable group, a decrease of 1ml
of BFR was associated with 9.2% more chance of having a
complication like AR, BOS or infection. Analysis of the stable
and BOS group alone demonstrated that, for a 1ml decrease
of BFR, the odds ratio of having BOS was 1.134. In the AR
group the risk of having AR increased with 6.8% and in the
infection group the risk increased with 10.6% with each
ml less BFR compared to the stable group (Table 3).
Performing stepwise regression analysis on the complete
study population demonstrated that a decrease of BFR with
10ml resulted in a significant decrease of the FEV1(%pred.)
with 4.43% and a significant increase of %neutrophils with
9.56% and IL8 protein with 9.67 pg/ml. We adjusted for
immunosuppressive therapy (cyclosporine/tacrolimus and
azathioprine/mycophenolate mofetil), and type of trans-
plantation in the analysis of FEV1. In the analysis forneutrophils and IL8 we adjusted for age, gender, type of
transplantation and therapy (Table 3).
The effect of airway colonization in the stable
group
To investigate the possible influence of airway colonization,
the stable group (n ¼ 52) was subdivided according to the
presence of organisms in the BAL. The infection group from
the first part is used as a reference. Colonization was
present in 24 samples and consisted of CMV (n ¼ 11),
Pseudomonas aeruginosa (n ¼ 6), Aspergillus fumigatus
(n ¼ 5), Candida albicans (n ¼ 2), coagulase-negative Sta-
phylococcus (n ¼ 1), Aspergillus niger (n ¼ 1), Alcaligenes
xylosoxidans (n ¼ 1), E. coli (n ¼ 1), Streptococcus penu-
moniae (n ¼ 1), Proteus mirabilis (n ¼ 1), Serratia marces-
cens (n ¼ 1) and Stenotrophomonas maltophilia (n ¼ 1).
Nine samples demonstrated a combined colonization. Varia-
tions were found for IL8 (p ¼ 0.0051), total number and
percentage of neutrophils (p ¼ 0.0037, po0.0001, respec-
tively), total number of lymphocytes (p ¼ 0.017), total
number of inflammatory cells (p ¼ 0.043) and total number
of macrophages (po0.0001). Eosinophils were not further
investigated as levels were negligible. Significant differ-
ences also were found for CRP (po0.0001) and BFR
(p ¼ 0.017) but not for FEV1(%pred.) (p ¼ 0.61) (Figure 2).
However, all the variations were caused by the infection
group. Bonferroni post hoc test showed no difference
between non-colonization and colonization samples of the
control group.
Discussion
In the present study, we evaluated whether BFR is related
to rejection or infection in LTx patients. BFR was signifi-
cantly decreased in LTx patients with infection or rejection
(acute or chronic). We also demonstrated the BFR to reflect
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Figure 1 BAL was performed in 115 LTx patients by instillation of two 50ml sterile saline aliquots. Results are expressed as volume
of BFR of the 100ml instilled (ml/100ml). (A) One-way analysis of variance demonstrated significant variations between the groups
(po0.0001). BFR was significantly decreased in patients with AR (po0.01, n ¼ 23), BOS (po0.001, n ¼ 31) and infection (po0.01,
n ¼ 9) compared to stable LTx patients (n ¼ 58). **po0.01 and ***po0.001. (B) Spearman correlation between FEV1 (%pred.) and BFR
of all patients (n ¼ 115). (C) Spearman correlation between the percentage of neutrophils in BAL and BFR of n ¼ 113 patients.
(D) Spearman correlation between IL8 (pg/ml) protein in BAL and BFR of all patients (n ¼ 115). (E) Correlation between the
percentage neutrophils in BAL and FEV1 (%pred.) of all patients (n ¼ 113). *po0.05; **po0.01 and ***po0.001.
BAL and airway neutrophilia 343the degree of airway obstruction (FEV1) and the inflamma-
tion in the lung (BAL neutrophilia and IL8). Each 1ml
decrease in BFR gives around 9.2% more risk of having
lung rejection (BOS or AR) or infection. This is accompaniedby a significant variation in FEV1(%pred.), %neutrophils
and IL8 protein in BAL. Airway colonization has always
been a problem in transplantation, as we have no idea
whether the (asymptomatic) presence of an organism in the
ARTICLE IN PRESS
Table 3 Logistic and single-regression analysis for variation of BFR.
Logistic regression analysis (Odds ratio associated with AR and/or BOS if BFR decreases with 1ml)
Odds ratio 95% Confidence interval p-Value
BOS or AR or infection (whole group) 1.092 1.049–1.138 o0.0001
BOS (AR and infection group not included) 1.134 1.063–1.211 0.0002
AR (BOS and infection group not included) 1.068 1.019–1.119 0.0061
Infection (AR and BOS group not included) 1.106 1.017–1.203 0.018
Single-regression analysis (changes if BFR decreases with 10ml)
Variation 95% Confidence interval p-Value
FEV1 (%pred.)
 4.43 1.37 to 7.49 0.0054
%Neutrophils in BALy 9.56 9.36–9.72 o0.0001
IL8 protein (pg/ml) in BALy 9.67 9.48–9.87 0.0015
CsA ¼ cyclosporine; FK506 ¼ tacrolimus; AZA ¼ azathioprine; MMF ¼ mycophenolate mofetil.
We adjusted for therapy (CsA/FK506 and AZA/MMF) and type of transplantation.
yWe adjusted for age gender, therapy (CsA/FK506 and AZA/MMF) and type of transplantation.
B.M. Vanaudenaerde et al.344airway influences its inflammatory status. The present study
documents that colonization, at least in stable LTX patients,
did not have any significant impact on the lung func-
tion, airway inflammation (neutrophils, IL8), blood CRP
and BFR.
BAL is a generally accepted clinical and research tool, to
assess inflammation of the airways in different patient
populations, including LTx patients. Technical procedures of
BAL were evaluated in the late 1990s by an ERS task force3
and recommended to use 5 aliquots of 50ml. The first was
designated as the bronchial fraction and the latter as the
alveolar fractions. This first bronchial fraction was recom-
mended to be discarded and analysis should be performed
on the other fractions, which were pooled. The article of
Martin et al. demonstrated, in patients with chronic
bronchitis, that cell profiles vary upon the volume used
for BAL. Neutrophils were predominantly present in the
early fractions and macrophages in the later fractions.2 The
importance of using standardized volumes and aliquots
for BAL sampling is now generally accepted. This is,
however, a problem in patients with severe lung diseases
(like COPD and LTx), as described in the article of Lofdahl
et al.8 Severely diseased lungs simply do not tolerate
high volumes. As a consequence, performing BAL already
presents a problem regarding the instillation volume. Using
too little volume, raises no problems as regard to instillation
and recovery, but only represents a bronchial lavage (BL).
Using a higher volume (combined with discarding the first
fraction) rather represents an alveolar lavage (AL), which
may be problematic with respect to recovery and later
analysis, not withstanding the possible clinical problems in
very sick patients. Our decision to use 100ml in 2 fractions
of 50ml, and to pool the fractions, is a result of this,
although this is not in accordance with the ERS Task force
guidelines. LTx patients simply do not always tolerate
instillation of higher volumes. Not discarding the first
(bronchial) fraction of the BAL was based on the potential
influence of the bronchial inflammation in the onset of
rejection and/or infection, which must not be under-
estimated in LTx patients.Until now, the LTx literature only discussed the volume
used for BAL.1 The importance of BFR was never discussed,
only sometimes mentioned6,7 or speculated on.15 In COPD
(where the major sites for airflow limitation are located
in peripheral airways and parenchyma), BFR volumes
were significantly lower compared to smoking control
subjects with normal lung function.16 Lofdahl et al.8
stipulated that this decrease makes BAL difficult to
interpret, as it may reflect larger airways rather than the
alveolar compartment. It would be tempting to eliminate all
BAL samples with a return below a certain volume (o30ml).
This can bias the results as most of the eliminated samples
are from the more diseased patients, which is confirmed by
the correlations between BFR and parameters like neutro-
philia, IL8 level, degree of BOS and FEV1. Consequently,
there is the dilemma of underestimating the airway
inflammation (loss of the more severely diseased patients),
on the one hand, or overestimating the inflammation (a
lower BFR reflects more BL containing more neutrophils), on
the other hand. In our study, no BAL samples were
eliminated for reasons of a low (o30ml) BFR, but, as a
consequence, we may have found more severe neutrophilic
inflammation.
Neutrophils are increased in some types of infection, in
BOS,17 at least in a subgroup,18 but also in AR.11 However,
even very high numbers of airway neutrophils may be found
in stable, AR and BOS samples. It would be tempting to
explain this by the presence of a secondary infection;
however, in our study this possible explanation was
eliminated based on clinical, bacteriological and histo-
pathological findings. High numbers of airway neutrophils
are not abnormal as it has also been demonstrated, although
not consistently, in several other studies.19–21 These papers
clearly illustrate that BAL neutrophils may be present even
in stable patients or in patients with an AR or BOS. A nice
example is the article by Slebos et al.5 Although no infection
is present and the median BAL neutrophil percentages in
stable, AR and BOS samples, were only 2%, 3% and 9% in both
the bronchial and the alveolar fraction, the neutrophil
percentages go up to 73%, 89% and 97%, respectively.3 These
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BAL and airway neutrophilia 345studies clearly indicate, as our own study, that neutrophil
numbers can sometimes be very high but not necessarily
relate to an infection as is sometime postulated.7 These
varying percentages may also partly be explained by the
method of performing BAL as discussed earlier.
Airway colonization could represent another possible
explanation for the high BAL neutrophilia. Some authors
even eliminate samples from their analysis when they are
colonized as little is known on its possible relevance.7
However, in this study the presence of colonization in the
stable group clearly demonstrates not to affect airway (BAL)
neutrophilia or any other inflammatory cell type. This was
confirmed by Ward et al.,22 who also found no difference in
airway inflammatory parameters between BAL samples with
bacteria or CMV present, compared to absence of organisms.
Therefore, it seems no longer necessary to exclude
colonized samples when there is no clinical, radiological or
pathological evidence for infection. There are, however, 2
remarks to be made. The definition of colonization can be a
matter of debate. We defined colonization as the presence
of an organism within the analyzed BAL sample, without
evidence for infection as defined earlier. We did not definecolonization as repeated isolation of the species from BAL
culture and/or repeatedly increased antibody levels in the
blood. The other possible shortcoming is that the colonized
group consisted of a mixture of several kinds of bacteria,
fungi and viruses. We can, therefore, not exclude that
colonization of some type of bacteria can induce inflamma-
tion or even influence the development of BOS, as we have
recently demonstrated for Pseudomonas and Pseudomonas-
like bacteria.23,24
Logistic regression analysis was performed to determine
an increase in risk of rejection (BOS/AR) or infection when
there is a decrease of BFR. A 9.2% higher risk was found for
having rejection (BOS/AR) or infection, if BFR decreases
with only 1ml, what makes it a very interesting tool in the
follow-up of the patients. Small changes were found
between AR, BOS and infection, respectively 6.8%, 13.4%
and 10.6. It is therefore clear that BFR itself can already
give some indication towards AR, BOS or infection and may
demand increased vigilance. It was also remarkable that a
10ml decrease of BFR is accompanied by an increase of
neutrophils with 9.5% and IL8 with 10.4 pg/ml and a
decrease of the FEV1(%pred.) with 4.5%, which again
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each other and that this is reflected in BFR.
The underlying mechanism that results in a decreased BFR
remains speculative but may be explained by the smaller
airway space (diameter) of the bronchioli and by the loss of
rigidity (increased compliance) of the airway wall, which are
caused by inflammation. Inflammatory cells and markers
(IL8) were investigated in order to have more information on
the mechanisms of this increased compliance. The key
element seems to be the increased airway neutrophilia and
related IL8 chemoattractant,13,17 which was found during
rejection and infection. It seems acceptable to postulate
that airway neutrophilia increases the collapsibility leading
to reduced BFR and a FEV1 decrease. It is tempting to
speculate whether a lower BFR is related with increased
neutrophilia/IL8 and so can be associated with azithromycin
responsiveness. Therefore, in our center when the BFR
starts to decrease we are alerted (not more not less) for the
lavage results (FEV1/BOS, neutrophilia, IL8) keeping in mind
that an increased neutrophlia/IL8 is a predictive factor for
the responsiveness of azithromycin.18,25
A possible limitation of the study can be the lack of a
healthy control group of asymptomatic non-smokers about
the same age (752 years). Especially as there is some
contradictory data regarding BFR between healthy indivi-
duals and stable LTx patients. On the one hand, Ward et al.6
and Zheng et al.7 reported a significant decrease of BFR in
stable LTx patients versus healthy individuals, but on the
other hand, an other report by Zheng et al.26 found no
difference between healthy individuals and stable LTx
patients, although each time 3 aliqouts of 60ml were used.
Martin et al.2 demonstrated the BFR to be lower in chronic
bronchitis patients compared to healthy individuals in the
later (alveolar) fraction and not in the early (bronchial
fractions). This was confirmed in LTx by Slebos et al.5 where
the BFR was lower in the alveolar fraction of patients with
BOS compared to stable patients but not in the bronchial
fraction.
In conclusion, the present results indicate that in LTx
a low BFR may predict the ongoing development of AR,
BOS or infection. A reduced BFR also correlates with
the FEV1, and the inflammation in the airways (IL8 and
neutrophils) and speculates about azithromycin responsive-
ness. The correlation between the decreased BFR and the
increased neutrophilic inflammation may indicate that
neutrophils are the cause of this increased compliance
of the airway wall. As a result, a low BFR may demand a
more intense vigilance for rejection and infection in LTx
patients. These data are not influenced by colonization of
the airways.Conflict of Interest
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